PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

BRAF inhibitors (BRAFi) are standard of care for the treatment of BRAF V600 mutation-driven metastatic melanoma, but can lead to paradoxical activation of the mitogen-activated protein kinase (MAPK) signalling pathway. This can result in the promotion of precancerous lesions and secondary neoplasms,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer
Autors principals: Tutuka, Candani S. A., Andrews, Miles C., Mariadason, John M., Ioannidis, Paul, Hudson, Christopher, Cebon, Jonathan, Behren, Andreas
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Letter to the Editor
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5490236/
https://ncbi.nlm.nih.gov/pubmed/28659148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-017-0684-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars